Navigation Links
Amgen Announces Evolocumab (AMG 145) Results From First 52-Week Study Of A PCSK9 Inhibitor To Reduce LDL Cholesterol
Date:11/19/2013

measured by the accepted standard preparative ultracentrifugation compared to baseline of the Phase 2 parent study. Patients who received one of six dosing regimens of evolocumab in the parent studies and received evolocumab and SOC in OSLER had persistent average LDL-C reductions of 50 percent at the end of the parent study vs. 52 percent at 52 weeks. Improvements in lipoprotein(a) and apolipoprotein B were also sustained up to 52 weeks.

Amgen will also host a webcast investor meeting at AHA on Tuesday, Nov. 19, at 7 p.m. CST. Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team and clinical investigators, will participate at the investor meeting to discuss data being presented at AHA.

Live audio of the investor meeting will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

OSLER Study Design
OSLER (Open Label Study of Long TERm Evaluation Against LDL-C Trial) is an open-label extension study to assess the long-term safety and efficacy of evolocumab. Patients who completed any of the four 12-week Phase 2 studies of evolocumab were eligible. The Phase 2 studies included:  

– MENDEL (Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Patients Currently Not Receiving Drug The
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
2. Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013
3. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
4. Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
5. Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus
6. Amgen And Servier Complete Product Collaboration Transaction
7. Amgen Announces 2013 Third Quarter Dividend
8. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
9. Amgen And Servier Announce Product Collaboration
10. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
11. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... On September 11, Pharma IQ conducted an interview with ... session that he will lead on “Stem Cells” at the ... 2015 in London. In the interview posted online ... respond to several questions on the current state of technologies ... toxicity, and future trends in the use of stem cells ...
(Date:9/29/2014)... 2014 Each year in the ... medical attention. In the military, burn injury is ... battlefield medical care. More than 800 service members ... wounds heal slowly, remain inflamed and often become ... debilitating and functionally damaging. While developments in supportive ...
(Date:9/29/2014)... /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") (OTC: ... that its three Promissory Note holders, two of whom ... each in July 2014 for a total of $ ... converted into 3,500,001 restricted common shares. Notes were repayable ... Note and the coupon were convertible into common shares ...
(Date:9/29/2014)... Transparency Market Research, in its report ... HPPS, by Application - Cancer, Metabolic, CVS, CNS & ... Delivery) - Global Industry Analysis, Size, Share, Growth, Trends ... peptide therapeutics market was worth US$14.1 billion in 2011 ... at an 8.7% CAGR. , The two main types ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4Faster Healing with Fewer Scars 2Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3
... MILWAUKEEThe growing popularity of digital music recorders, digital ... Brady Corporation 's recent acquisition of ID ... manufacturer and supplier of pressure sensitive die-cut components ... Brady Asia-Pacific Allan Klotsche, this acquisition, along with ...
... In order to surpass its original goal for life-long learning ... (ADL) Co-Laboratory has plans to move from University Research Park ... will make the move Sept. 1, a bit behind ... While delays in the approval processes are to blame for ...
... recently announced it received a Phase I small business ... Cancer Institute . , ,The grant, according to chief executive ... rapidly measure the activity of enzymes that are relevant to ... could develop a way to quickly quantify enzyme activity that ...
Cached Biology Technology:Brady continues growth through Asian acquisition 2Academic ADL Co-Lab moving to downtown Madison 2Academic ADL Co-Lab moving to downtown Madison 3
(Date:9/29/2014)... simple spheres of fluid, not normally considered capable of ... made droplets of alcohol move through water. In the ... able to move on your own to be ... organisms. But also non-living entities can be self-moving, report ... Chemical Technology in Prague, Czech Republic. , The researchers ...
(Date:9/29/2014)... This news release is available in French . ... 29th, 2014 - The number of days an expectant ... (1998) predicts the epigenetic profile of her child, a ... University Institute and McGill University have detected a distinctive ... aftermath of the massive Quebec ice storm. Five months ...
(Date:9/29/2014)... with Multiple Sclerosis (MS) were able to safely tolerate ... to a study published today in the journal ... is the first of its kind, was conducted by ... Celgene Corporation and collaborators at several other institutions. ... early signals in the data also suggested that a ...
Breaking Biology News(10 mins):Scientists make droplets move on their own 2Cells from placentas safe for patients with multiple sclerosis 2
... (Santa Barbara, Calif.) New research at UC Santa Barbara ... develop. The study is part of the campus,s expanding vision ... versions of The Proceedings of the National Academy of ... (IOVS). The scientists document how they used mice ...
... the collaboration of the Spanish Foundation for Biodiversity, the Charter ... the AZTI-Tecnalia R+D Centre will be studying the re-stocking of ... the months of May, June and July, respectively, in three ... gather the information needed to be able to manage the ...
... This release is available in German . ... research in Germany, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) ... was taken by the appropriate Grants Committee in Bonn. The ... four and half years, during which time they will receive ...
Cached Biology News:UCSB scientists make strides in vision research 2A study will enable the survival and growth of the 3 development phases of the European eel 2DFG establishes 18 new research training groups 2DFG establishes 18 new research training groups 3DFG establishes 18 new research training groups 4DFG establishes 18 new research training groups 5DFG establishes 18 new research training groups 6DFG establishes 18 new research training groups 7DFG establishes 18 new research training groups 8DFG establishes 18 new research training groups 9DFG establishes 18 new research training groups 10
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
... Prepared by a modification of the ... Biotechnol. Bioeng., 11 , ... will yield an A 260 ... water (1 cm light path). Physical ...
... Dithiothreitol DTT White solid.. PACKAGED UNDER ... thiols, so reaction is "driven" to completion. A ... waxy surfactant found in many other preparations. Blocks ... Purity: ≥97% by titration. Contaminants: Heavy ...
Biology Products: